Free flowing solid dispersions of the anti-HIV drug UC 781 with Poloxamer 407 and a maximum amount of TPGS 1000: Investigating the relationship between physicochemical characteristics and dissolution behaviour

European Journal of Pharmaceutical Sciences

Volumn 35, Issue 1-2, 2008, Pages 104-113

  Goddeeris, Caroline ^a   Van den Mooter, Guy ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Drug dissolution; Eutectic phase behaviour; Free flowing powder; Solid dispersion; TPGS 1000; UC 781

Indexed keywords

N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; POLOXAMER; TOCOFERSOLAN;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; EMULSION; PHASE TRANSITION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ALGORITHMS; ANILIDES; ANTI-HIV AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DESICCATION; DRUG CARRIERS; DRUG COMPOUNDING; EXCIPIENTS; FURANS; HYDROLYSIS; POLOXAMER; POLYETHYLENE GLYCOLS; SOLUBILITY; VITAMIN E; X-RAY DIFFRACTION;

EID: 48849096338     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.06.010     Document Type: Article

References (23)

1. Amidon G.L., Lennernäs H., Shah V.P., and Crison J.R. Theoretical basis for a biopharmaceutical drug classification: the correlation of in vivo drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
2. Balzarini J., Brouwer W.G., Dao D.C., Osika E.M., and De clercq E. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob. Agents Chemother. 40 (1996) 1454-1466
3. Balzarini J., Naesens L., Verbeken E., Laga M., Van Damme L., Parniak M., van Mellaert L., Anné J., and De Clercq E. Preclinical studies on the thiocarboxanilide UC 781 as a virucidal agent. AIDS 12 (1998) 1129-1138
4. Barnard J., Borkow G., and Parniak M.A. The thiocarboxanilide non-nucleoside UC 781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 36 (1997) 7786-7792
5. Borkow G., Barnard J., Belmonte A., Nguyen T.M., Wainberg M.A., and Parniak M.A. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC 781, a thiocarboxanilide non-nucleoside inhibitor of HIV-1 reverse transcriptase. J. Virol. 71 (1997) 3023-3030
6. Brouwers J., Tack J., Lammert F., and Augustijns P. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir. J. Pharm. Sci. 95 (2006) 372-383
7. Charman S.A., Charman W.N., Rogge M.C., Wilson T.D., Dutko F.J., and Pouton C.W. Self-emulsifying systems: formulation and biological evaluation of an investigative lipophilic compound. Pharm. Res. 9 (1992) 87-94
8. Chiou W.L., and Riegelmans S. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 60 (1971) 1281-1302
9. Constantinides P. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res. 12 (1995) 1561-1572
10. Damian F., Blaton N., Desseyn H., Clou K., Augustijns P., Naesens L., Balzarini J., Kinget R., and Van den Mooter G. Solid state properties of pure UC 781 and solid dispersions with polyvinylpyrrolidone (PVPK30). J. Pharm. Pharmacol. 53 (2001) 1109-1116
11. Ford J.L. The current status of solid dispersions. Pharm. Acta Helv. 61 (1986) 69-88
12. Goddeeris C., Coacci J., and Van den Mooter G. Correlation between digestion of the lipid phase of SMEDDS and release of the anti-HOV drug UC 781 and the anti-micotic drug enilconazole from smedds. Eur. J. Pharm. Biopharm. 66 (2007) 173-181
13. Hancock B.C., and Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86 (1997) 1-12
14. Khoo S.-M., Porter C., and Charman W. The formulation of Halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: physical stability and absolute bioavailability assessment. Int. J. Pharm. 205 (2000) 65-78
15. Leuner C., and Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50 (2000) 47-60
16. Liu R. Water-Insoluble Drug Formulation (2000), Interpharm Press, Denver, Colorado
17. Ozeki T., Yuasa H., and Kanaya Y. Application of the solid dispersion method to the controlled release of medicine. IX. Difference in the release of flurbiprofen from solid dispersions with poly(ethylene oxide) and hydroxypropylcellulose and the interaction between medicine and polymers. Int. J. Pharm. 115 (1997) 209-217
18. Sekigushi K., and Obi N. Studies on absorption of eutectic mixtures. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull. 9 (1961) 866-872
19. Shah N.H., Carvajal M.T., Patel C.I., Infeld M.H., and Melick A.W. Self-emulsifying drug delivery systems with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int. J. Pharm. 106 (1994) 15-23
20. Shin S.-C., and Kim J. Physicochemical characterisation of solid dispersion of furosemide with TPGS. Int. J. Pharm. 251 (2003) 79-84
21. Stupak E.I., and Bates T.R. Enhanced absorption and dissolution of reserpine-polyvinylpyrrolidone coprecipitates. J Pharm. Sci. 61 (1972) 400-404
22. Stupak E.I., and Bates T.R. Enhanced absorption of digitoxin from orally administered digitoxin-polyvonylpyrrolidone coprecipitates. J. Pharm. Sci. 62 (1973) 1806-1809
23. Verheyen S., Blaton N., Kinget R., and Van den Mooter G. Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions. Int. J. Pharm. 249 (2002) 45-48